Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 9,592 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the sale, the chief executive officer owned 694,354 shares in the company, valued at $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Ryan Fukushima also recently made the following trade(s):

• On Monday, January 5th, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $64.26, for a total transaction of $321,300.00.
• On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $75.72, for a total transaction of $378,600.00.

Tempus AI Price Performance

Shares of TEM opened at $58.37 on Friday. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The firm’s fifty day simple moving average is $62.35 and its 200-day simple moving average is $73.39. The firm has a market capitalization of $10.38 billion, a price-to-earnings ratio of -49.05 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TEM shares. Morgan Stanley upped their price objective on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Needham & Company LLC upped their price target on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Canaccord Genuity Group cut their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Piper Sandler reduced their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, Robert W. Baird began coverage on shares of Tempus AI in a research report on Tuesday. They issued an “outperform” rating and a $59.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $85.92.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in shares of Tempus AI by 21.5% in the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after acquiring an additional 65,836 shares during the period. Vident Advisory LLC raised its position in Tempus AI by 5.3% in the 4th quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock valued at $613,000 after purchasing an additional 522 shares during the last quarter. Oracle Investment Management Inc. acquired a new stake in Tempus AI during the 4th quarter worth $384,000. EP Wealth Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth $553,000. Finally, Regal Partners Ltd purchased a new position in Tempus AI during the 4th quarter worth $531,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.